Dabrafenib

Short Description:

API’s Name Indication Innovator Patent Expiry Date(The U.S)
Dabrafenib  Melanoma  Novartis(GSK R&D)  Jul.20, 2030


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us